分组1 - CeriBell, Inc. reported a quarterly loss of $0.36 per share, better than the Zacks Consensus Estimate of a loss of $0.43, representing an earnings surprise of +16.76% [1] - The company posted revenues of $24.78 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 4.40%, and compared to revenues of $18.53 million a year ago [2] - CeriBell, Inc. has surpassed consensus EPS estimates for four consecutive quarters [2] 分组2 - The stock has underperformed the market, losing about 8.9% since the beginning of the year, while the S&P 500 has declined by only 0.1% [3] - The current consensus EPS estimate for the coming quarter is -$0.37 on revenues of $26.01 million, and for the current fiscal year, it is -$1.46 on revenues of $112.76 million [7] - The Zacks Industry Rank for Medical - Products is in the bottom 45% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

CeriBell (NasdaqGS:CBLL) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsBrian Johnston - Investor Relations ContactJane Chao - Co-Founder and CEOJeffrey Cohen - Managing Director and Director of Equity ResearchScott Blumberg - CFOTravis Steed - Managing Director of Equity ResearchConference Call ParticipantsBill Plovanic - Managing Director of Equity Research and Medical Technology AnalystBrandon Vazquez - Equity Research AnalystMarie Thibault - Managing Director and Medical Technol ...

CeriBell (NasdaqGS:CBLL) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsBrian Johnston - Investor Relations ContactJane Chao - Co-Founder and CEOJeffrey Cohen - Managing Director and Director of Equity ResearchScott Blumberg - CFOTravis Steed - Managing Director of Equity ResearchConference Call ParticipantsBill Plovanic - Managing Director of Equity Research and Medical Technology AnalystBrandon Vazquez - Equity Research AnalystMarie Thibault - Managing Director and Medical Technol ...

CeriBell (NasdaqGS:CBLL) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker7Hello, and welcome to the CeriBell Q4 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press star 1 again. Thank you. I will now turn the call ove ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR (I.R.S. Employer Identification No.) Sunnyvale, CA 94085 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (800) 436-0826 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION ...

Fourth Quarter 2025 & Recent Highlights "2025 was a milestone year for Ceribell," said co-founder and CEO Jane Chao, Ph.D. "We accelerated adoption across new and existing accounts, broadened the age range of our seizure detection algorithm to include pediatric and neonatal populations, and achieved critical regulatory milestones, unlocking incremental market opportunities that we believe exceed $1.5 billion. As we enter the new year, we believe these accomplishments position us well to drive continued grow ...

SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 & Recent Highlights Reported total revenue of $24.8 million in the fourth quarter of 2025, a 34% increase compared to the same period in 2024Delivered total revenue of ...

Core Insights - CeriBell, Inc. is participating in two upcoming investor conferences to enhance investor engagement and showcase its innovative medical technology solutions [1][2]. Group 1: Upcoming Events - CeriBell will present at the Raymond James 47 Annual Institutional Investors Conference on March 2, 2026, at 1:00 p.m. PST / 4:00 p.m. EST [2]. - The company will also participate in a fireside chat at the TD Cowen 46 Annual Health Care Conference on March 3, 2026, at 10:50 a.m. PST / 1:50 p.m. EST [2]. Group 2: Company Overview - CeriBell is focused on transforming the diagnosis and management of patients with serious neurological conditions through its innovative Ceribell System [3]. - The Ceribell System is a point-of-care electroencephalography (EEG) platform designed for acute-care settings, enabling rapid diagnosis and continuous monitoring of neurological conditions [3]. - The system is FDA-cleared for detecting seizures and delirium in intensive care units and emergency rooms across the U.S. [3].

Core Viewpoint - CeriBell, Inc. is set to release its financial results for Q4 and the full year of 2025 on February 24, 2026, with a conference call scheduled to discuss these results [1]. Company Overview - CeriBell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions [3]. - The company has developed the Ceribell System, a novel point-of-care electroencephalography (EEG) platform designed for acute-care settings [3]. - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions [3]. - The system is FDA-cleared for detecting seizures and delirium in intensive care units and emergency rooms across the U.S. [3]. - CeriBell is headquartered in Sunnyvale, California [3].

Core Insights - CeriBell has developed a neuromonitoring platform that simplifies EEG acquisition, allowing nurses to set up in minutes instead of waiting for specialized technicians [1] - The company focuses on seizure detection in acute care settings, with a significant market opportunity in the U.S. estimated at over $2 billion [2] - CeriBell projects a revenue of $87 million to $89 million for the current year, reflecting a 34% year-over-year growth with an 88% gross margin [2] - The total addressable market (TAM) for CeriBell is expected to grow from $2 billion to $3.5 billion by 2025, driven by expansion into pediatric and neonate populations and gaining FDA clearance for delirium detection [2] Company Overview - CeriBell's platform includes an AI-powered algorithm named Clarity, which detects various neurological disorders [1] - The company has made significant progress in expanding its market presence and product offerings [2] Market Opportunity - The focus on seizure detection in acute care settings highlights the prevalence of seizures and the need for efficient monitoring solutions [3]